Abstracts tagged "Effective"

Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Masahiro Tada¹, Tatsuya Koike², Akihiro Tamori³, Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
Abstract Number: 856 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout
Eric Jutkowitz¹, Karen Kuntz², Laura T Pizzi³ and Hyon Choi^4,5, ¹Divisions of Health Policy and Management (EJ, KMK), School of Public Health, University of Minnesota, Minneapolis, MN, ²Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ³Thomas Jefferson University, Philadelphia, PA, ⁴Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The new 2012 ACR guidelines for the management of gout have provided updated recommendations; however, the employed method do not address the societal costs…
Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Paul Emery¹, Annette Szumski², Jack Bukowski³, Eustratios Bananis² and Lisa Marshall⁴, ¹Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc., Collegeville, PA
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].